Literature DB >> 21475446

Comparison of serological and nucleic Acid based assays used to diagnose hepatitis C virus (HCV) infection in acute and chronic liver diseases.

M Irshad1, I Dhar, Shiwani Singh, S Kapoor.   

Abstract

BACKGROUND: This study reports a comparative diagnostic potential of three different assay systems used to detect HCV infection in acute and chronic liver diseases.
METHODS: A total number of 364 patients with various types of liver diseases were analyzed for hepatitis C virus (HCV) core antigen using Enzyme Immuno Assay (EIA), HCV-RNA by RT-PCR and anti-HCV antibodies by third generation EIA system. Simultaneously these patients were also tested for markers of other hepatitis viruses, notably, hepatitis A, B, C, D and E. In some cases, even transfusion transmitted virus (TTV) was tested using TTV-DNA as the marker of TTV infection.
RESULTS: Analysis of results demonstrated the presence of hepatitis B, C and E in different proportions of patients belonging to these liver diseases. Hepatitis A and D infections could not be detected in these cases TTV infection was prevalent in different liver diseases in different proportions. Though none of control sera demonstrated hepatitis A-E infection, however, TTV infection was noted in control group also. When we analysed all the sera for HCV infection using these different assay systems, we found HCV core, HCV-RNA and anti-HCV antibodies in 18.3%, 18.3% and 5.83% cases of acute viral hepatitis (AVH), 13.3 %, 13.3% and 46.6% cases of chronic viral hepatitis (CVH), 23.8%, 23.8% and 23.8% cases with cirrhosis of liver and 20%, 17.5% and 10% cases respectively, of fulminant hepatic failure (FHF) patients. Whereas HCV core and HCV-RNA assays were comparable and predominantly positive in acute cases (AVH and FHF), anti-HCV antibodies were detected in high proportions in chronic liver diseases. Cirrhosis patients showed all the markers in equal proportions. This pattern of HCV markers remains unaffected by co-infection of HCV with other hepatitis viral infections.
CONCLUSION: In conclusion, where HCV core and HCV-RNA are best diagnostic markers in acute liver diseases, anti-HCV diagnoses high proportion of HCV cases in chronic liver diseases. This diagnostic pattern is not changed on co-infection of HCV with other viral infections.

Entities:  

Keywords:  Core; HCV; Hepatitis; PCR; TTV

Year:  2007        PMID: 21475446      PMCID: PMC3068650     

Source DB:  PubMed          Journal:  Int J Health Sci (Qassim)        ISSN: 1658-3639


  16 in total

Review 1.  Monitoring response to antiviral treatment by serum hepatitis C virus core antigen: too early to take shortcuts?

Authors:  Mario U Mondelli
Journal:  J Hepatol       Date:  2004-03       Impact factor: 25.083

2.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

3.  The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway.

Authors:  A L Ruff; F G Guarnieri; K Staveley-O'Carroll; R F Siliciano; J T August
Journal:  J Biol Chem       Date:  1997-03-28       Impact factor: 5.157

Review 4.  Use and interpretation of virological tests for hepatitis C.

Authors:  Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

5.  Total HCV core antigen assay: a new marker of hepatitis C viremia for monitoring the progress of therapy.

Authors:  Alessandro R Zanetti; Luisa Romanò; Maurizia Brunetto; Massimo Colombo; Giorgio Bellati; Charles Tackney
Journal:  J Med Virol       Date:  2003-05       Impact factor: 2.327

Review 6.  The role of core antigen detection in management of hepatitis C: a critical review.

Authors:  Katja Seme; Mario Poljak; Dunja Z Babic; Tina Mocilnik; Adriana Vince
Journal:  J Clin Virol       Date:  2005-02       Impact factor: 3.168

7.  Acute and chronic hepatitis revisited. Review by an international group.

Authors: 
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

8.  Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA.

Authors:  E Tanaka; C Ohue; K Aoyagi; K Yamaguchi; S Yagi; K Kiyosawa; H J Alter
Journal:  Hepatology       Date:  2000-08       Impact factor: 17.425

9.  Acute liver failure. Experience with 145 patients.

Authors:  B N Tandon; Y K Joshi; M Tandon
Journal:  J Clin Gastroenterol       Date:  1986-12       Impact factor: 3.062

10.  Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication.

Authors:  Magali Bouvier-Alias; Keyur Patel; Harel Dahari; Stéphanie Beaucourt; Patrick Larderie; Lawrence Blatt; Christophe Hezode; Gaston Picchio; Daniel Dhumeaux; Avidan U Neumann; John G McHutchison; Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

View more
  1 in total

1.  Detection of hepatitis C virus (HCV) among health care providers in an Egyptian university hospital: different diagnostic modalities.

Authors:  Rehab H El-Sokkary; Rehab M Elsaid Tash; Takwa E Meawed; Omnia S El Seifi; Eman M Mortada
Journal:  Infect Drug Resist       Date:  2017-10-17       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.